Market revenue in 2023 | USD 29.0 million |
Market revenue in 2030 | USD 42.9 million |
Growth rate | 5.7% (CAGR from 2023 to 2030) |
Largest segment | Other brands |
Fastest growing segment | QFT-Plus (QuantiFERON-TB Gold Plus) |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | QFT-Plus (QuantiFERON-TB Gold Plus), Other brands |
Key market players worldwide | BioMerieux SA, Roche Holding AG, Abbott Laboratories, Sanofi SA, PerkinElmer, Becton Dickinson & Co, Serum Institute of India Pvt. Ltd., Lionex Diagnostics & Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to latent tuberculosis infection detection market will help companies and investors design strategic landscapes.
Other brands was the largest segment with a revenue share of 73.79% in 2023. Horizon Databook has segmented the UK latent tuberculosis infection detection market based on qft-plus (quantiferon-tb gold plus), other brands covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the UK latent tuberculosis infection detection market , including forecasts for subscribers. This country databook contains high-level insights into UK latent tuberculosis infection detection market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account